<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657602</url>
  </required_header>
  <id_info>
    <org_study_id>9588</org_study_id>
    <nct_id>NCT03657602</nct_id>
  </id_info>
  <brief_title>Immediate Postpartum Insertion of Contraceptive Intrauterine Devices</brief_title>
  <official_title>Immediate Postpartum Insertion of Kyleena vs Mirena Contraceptive Intrauterine Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized trial, investigators intend to determine the expulsion and discontinuation&#xD;
      rate of immediate postpartum intrauterine devices in the patient population of the University&#xD;
      of Oklahoma Women's Healthcare Specialists Clinic (OUWHSC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Between 40-57% of women report having unprotected intercourse prior to the 6 week postpartum&#xD;
      visit. Immediate postpartum long-acting reversible contraception (LARC) is extremely&#xD;
      important in preventing short-interval and unintended pregnancies. The postpartum period is&#xD;
      an excellent time for intrauterine device (IUD) or implant insertion as women are often&#xD;
      highly motivated to prevent unwanted pregnancies at this time. Per the American College of&#xD;
      Obstetrics and Gynecology (ACOG), expulsion rates for immediate postpartum IUD insertion are&#xD;
      higher than for interval or post-abortion insertion. Despite the higher expulsion rate of&#xD;
      immediate postpartum IUD placement over interval placement, cost-benefit analysis data&#xD;
      strongly suggest the superiority of immediate placement in reduction of unintended pregnancy,&#xD;
      especially for women at greatest risk of not attending the postpartum follow-up visit. This&#xD;
      study will randomly allocate participants one to one to the Kyleena or the Mirena IUD group,&#xD;
      and participants will be blinded to allocation of groups. Participants will follow up at&#xD;
      routine postpartum visit within 4 weeks of delivery, and a second follow up will be performed&#xD;
      at 10 weeks. Ultimately, this study will attempt to provide more detailed information on the&#xD;
      difference of rates of expulsion and discontinuation of the different-sized Mirena and&#xD;
      Kyleena intrauterine devices.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly allocated one to one to the Kyleena or Mirena group and assessment will occur in parallel</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participant will be blinded to group assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Expulsion of intrauterine contraception</measure>
    <time_frame>within 10 weeks of placement</time_frame>
    <description>IUD string check and ultrasound check</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Discontinuation of intrauterine contraception</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Date IUD is removed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Contraceptive Kyleena</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Kyleena Intrauterine System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Contraceptive Mirena</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Mirena Intrauterine System</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kyleena Intrauterine System</intervention_name>
    <description>Participant will be randomly allocated to this intervention</description>
    <arm_group_label>Contraceptive Kyleena</arm_group_label>
    <other_name>levonorgestrel intrauterine system</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirena Intrauterine System</intervention_name>
    <description>Participant will be randomly allocated to this intervention</description>
    <arm_group_label>Contraceptive Mirena</arm_group_label>
    <other_name>levonorgestrel intrauterine system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  desire an intrauterine device as postpartum contraception&#xD;
&#xD;
          -  want to avoid pregnancy for at least 1 year&#xD;
&#xD;
          -  are currently pregnant&#xD;
&#xD;
          -  desire immediate postpartum IUD insertion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known uterine or cervical anomaly&#xD;
&#xD;
          -  untreated cervical infection&#xD;
&#xD;
          -  untreated cervical infection&#xD;
&#xD;
          -  pelvic infection within 3 months of the study&#xD;
&#xD;
          -  recent (within last 3 months) or active intrauterine infection&#xD;
&#xD;
          -  genital bleeding of unknown etiology&#xD;
&#xD;
          -  history of postpartum or postabortal sepsis&#xD;
&#xD;
          -  cervical cancer or carcinoma in suit&#xD;
&#xD;
          -  plan to leave Tulsa area within 10 weeks postpartum&#xD;
&#xD;
          -  allergy to device ingredients&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valorie Owens, MSW</last_name>
    <role>Study Director</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monica Henning, MD</last_name>
    <phone>918-660-8350</phone>
    <email>Monica-Henning@ouhsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Gold, MD</last_name>
    <phone>918-660-8352</phone>
    <email>Karen-Gold@ouhsc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Oklahoma - Tulsa</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keri K Ellard, MD</last_name>
      <phone>918-660-8350</phone>
      <email>keri-ellard@ouhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vickie S Minton, RN</last_name>
      <phone>918-660-8350</phone>
      <email>vickie-minton@ouhsc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

